The global platinum based Cancer drugs market size is expected to reach USD 1,814.1 Million by 2026 according to a new study by Polaris Market Research. The report “Global Platinum Based Cancer Drugs Market Share, Size, Trends, Industry Analysis Report By Drug Type (Cisplatin, Oxaliplatin, Carboplatin, Other), Application (Colorectal, Ovarian, Lung, & Other Cancer); By Regions, Segments & Forecast, 2019 – 2026”gives a detailed insight into current market dynamics and provides analysis on future market growth.
Drugs based on platinum have become a major component of cancer therapy; about half of all patients undergoing chemotherapy receive a platinum drug. The widespread use of platinum agents in cancer treatment started with Barnett Rosenberg’s discovery of cisplatin’s antineoplastic activity in the 1960s.
According to the National Cancer Institute, the instances of new cases per year is expected to rise to 23.6 million by 2030. Nevertheless, the major limitations of this industry worldwide are the drug-related side effects and resistance growth. Recent developments in platinum based cancer drugs include the development of analog platinum drugs such as platinum carrier molecule complexes to boost targeted concentration of drugs in cancer tumor. This increasing number of cancer instances is expected to drive the growth of the global platinum cancer drug market during the forecast period.
The platinum based cancer drugs market can be categorized in terms of product type as oxaliplatin, cisplatin, carboplatin, and others. Cisplatin is the most commonly used for treating certain malignancies. It is particularly effective in testicular cancer and is intravenously administered. Carboplatin, a derivative of cisplatin, is used to treat multiple cancers like ovaries, lungs, brains, and so on. Cisplatin’s segment maintained the largest market share in 2018 and is expected to remain dominant over the forecast period. Based on application, the global market is divided into ovarian, lung, testicular, colorectal, and other cancer. The lung cancer segment dominated the market in 2018 due to the high incidence among the world’s population.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/platinum-based-cancer-drugs-market
Due to enhanced disease prevalence, enhanced awareness, increased per capita income, and enhanced health care infrastructure, the Asia Pacific market is anticipated to develop at the largest CAGR. North America dominated the global market in 2018 due to the high incidence of cancer in the region, developments in these drugs and recent FDA approvals. United States is the world’s largest drug market. This has led to the dominance of North America in the global platinum cancer drug market. The U.S. pharmaceutical industry is the largest domestic market in the world. It is the world’s biggest continental pharmaceutical market together with Canada and Mexico. More than 45 percent of the worldwide pharmaceutical industry is held by the United States alone. This share was valued at approximately $446 Million in 2016. Many of the top worldwide firms are from the U.S. In 2016, six out of the top 10 firms were based on sheer pharmaceutical income from the United States.
Major players in the platinum cancer drug market include Sanofi, Pfizer, Inc., Mylan N.V., Ask-Pharma, Sun Pharmaceutical Industries Ltd., Accord Healthcare, Novartis AG, Teva Pharmaceutical Industries Ltd., Guizhou YiBai Pharmaceutical Co., Ltd., SK Chemicals, Qilu Pharmaceutical Co., Ltd., Dr. Reddy’s Laboratories Ltd., Debiopharm Group, and Jiangsu Hengrui Pharmaceutical Co., Ltd.
Polaris Market research has segmented the Platinum Based Cancer Drugs market report on the basis of drug type, application type, and region
Platinum Based Cancer Drug Type Outlook (Revenue, USD Million, 2015 – 2026)
Platinum Based Cancer Drugs Application Type Outlook (Revenue, USD Million, 2015 – 2026)
- Colorectal Cancer
- Ovarian Cancer
- Lung Cancer
Platinum Based Cancer Drugs Regional Outlook (Revenue, USD Million, 2015 – 2026)
- North America
- Asia Pacific
- South Korea
- Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa